BioMarin's new CEO had promised Wall Street there would be deals, and with Amicus, it has one the market likes.

BioMarin said it is acquiring Amicus Therapeutics, maker of rare-disease drugs, for $4.8 billion. A new FDA program meant to ...

BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn ...

The Trump administration has announced sweeping policies that, if enacted, could effectively end gender-affirming care for ...

Two government officials told STAT that the White House has been involved in final decisions about the FDA's new priority ...

The U.K. government wants to boost the local life sciences industry, and it hopes to entice American venture capital firms to ...

The award is in response to an “unsolicited proposal,” according to documents in the Federal Register. The University of ...

The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.

Every major pharmaceutical breakthrough in the past 40 years started with taxpayer-funded basic research: mRNA vaccines, ...

An FDA program to fast-track drug reviews has become a way for the White House to influence which medicines make their way fastest to patients ...

President Trump weighs in on a debate between hard-liners on marijuana and those who want more research on its medical uses.

A Trump administration change to how NIH awards grants has sharply reduced early-stage investigators’ odds of securing ...